Therapy relaunches as Clinical Practice in 2012
New name, new look, new content – Therapy relaunches as Clinical Practice in 2012
Future Medicine Ltd has today announced the rebranding of the journal Therapy (ISSN:1475-0708) under the new name of Clinical Practice (ISSN:2044-9038). The new title is designed to more aptly reflect the needs of the readership and the future direction for the journal. The journal addresses key issues and controversies in modern medicine.
Over the past eight years Therapy has established a solid readership as a general medical title. The journal covers a broad spectrum of medical disorders and reaches out to a wide audience including clinicians, decision-makers, researchers and a range of professionals in the healthcare community. Now, as well as the new name, cover design and page layouts, the relaunched title includes novel article types drawing on expert opinion regarding new approaches to managing and treating disease, identifying clinical burden and unmet needs, as well as analyzing the implications of recently published guidelines for daily practice.
The editorial direction of Clinical Practice is driven by three Editors-in-Chief; Gregory YH Lip (City Hospital, Birmingham, UK), Samy I McFarlane (State University of New York, NY, USA) and James Larkin (Royal Marsden Hospital, London, UK), who coordinate efforts to achieve the highest quality content across the most topical subjects in modern medicine. The wider Editorial Board consists of influential clinicians representative of their respective fields to ensure a good balance of published content and to provide moderation and evaluation during the publication process.
The Editors-in-Chief and publishers are keen to point out that the journal’s high editorial standards will be maintained and nurtured. Elisa Manzotti, Editorial Director of FSG, remarked that, “We are delighted with the new look and direction of Clinical Practice and look forward to working with the Editors-in-Chief, Editorial Board and referees, and our author base of internationally renowned clinicians, to provide a platform for expert opinion, commentary and debate across the full spectrum of modern medicine in the coming years.”
Samy I McFarlane commented that, "Clinical Practice is designed for busy practitioners, intended to put imminently relevant information at their fingertips. This is particularly vital given the increasing workload and the dwindling time for the health care providers to keep up with the plethora of medical information emerging on a daily basis".
The editorial office is now actively soliciting contributions of reviews, perspectives and editorial articles for Clinical Practice. For a full range of the exciting new article types included in Clinical Practice please see our Author Guidelines. If you are interested in contributing any of the article types listed then please contact the Managing Commissioning Editor, Laura McGuinness, on l.mcguinness@futuremedicne.com.
Selected content from the first issue of Clinical Practice can be viewed at www.futuremedicine.com/loi.cpr. If you are interested in receiving a free 30-day online trial to evaluate the journals content please contact info@futuremedicine.com, quoting CPR12PR.
--Ends--
For further information on Clinical Practice, please contact the Victoria Lane, Senior Manager, Future Science Group.
T: +44 (0) 20 8371 6090 E: v.lane@futuremedicine.com
ABOUT CLINICAL PRACTICE
Clinical Practice provides a forum to address all aspects facing clinical practitioners today, from exploring unmet therapeutic needs to analyzing the implications of real-world evidence, applications of clinical guidelines and multidisciplinary approaches to care.
Editors in Chief
Samy I McFarlane, State University of New York, NY, USA
Gregory YH Lip, City Hospital, Birmingham, UK
James Larkin, Royal Marsden Hospital, London, UK
Topics include:
• Application of Phase III clinical trial results in clinical practice
• Findings from Phase IV/post-marketing studies
• Understanding of unmet clinical needs and therapeutic burden
• Practical approaches to disease management
• Evidence-based treatment guidelines
• Personal perspectives in treating a disease
• Multidisciplinary team approaches to care
Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.
ABOUT FUTURE SCIENCE GROUP AND FUTURE MEDICINE LTD
Future Science Group, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain.
Through its imprints, Future Medicine Ltd and Expert Reviews Ltd, Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. For more information please access www.futuremedicine.com.